226 related articles for article (PubMed ID: 31242460)
1. Ras association domain family protein 1a hypermethylation and PD-L1 expression in ovarian cancer: A retrospective study of 112 cases.
Zhu X; Yang H; Lang J; Zhang Y
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():103-108. PubMed ID: 31242460
[TBL] [Abstract][Full Text] [Related]
2. The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.
Zhu X; Zhao L; Lang J
Int J Gynecol Cancer; 2018 Oct; 28(8):1514-1519. PubMed ID: 30045136
[TBL] [Abstract][Full Text] [Related]
3. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
4. Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers.
Ma L; Guo Q; Ma Y; Liu FR; Shen XY
Eur J Gynaecol Oncol; 2009; 30(4):370-4. PubMed ID: 19761124
[TBL] [Abstract][Full Text] [Related]
5. [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors].
Ma L; Zhang JH; Liu FR; Zhang X
Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):657-9. PubMed ID: 16438885
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
[TBL] [Abstract][Full Text] [Related]
7. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients.
Pawłowska A; Kwiatkowska A; Suszczyk D; Chudzik A; Tarkowski R; Barczyński B; Kotarski J; Wertel I
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768993
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma.
Fendri A; Masmoudi A; Khabir A; Sellami-Boudawara T; Daoud J; Frikha M; Ghorbel A; Gargouri A; Mokdad-Gargouri R
Cancer Biol Ther; 2009 Mar; 8(5):444-51. PubMed ID: 19221469
[TBL] [Abstract][Full Text] [Related]
10. Relationship between RAS Association Domain Family Protein 1A Promoter Methylation and the Clinicopathological Characteristics in Patients with Ovarian Cancer: A Systematic Meta-Analysis.
Wang H; Cui M; Zhang S; He J; Song L; Chen Y
Gynecol Obstet Invest; 2018; 83(4):349-357. PubMed ID: 29130987
[TBL] [Abstract][Full Text] [Related]
11. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
[TBL] [Abstract][Full Text] [Related]
12. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
13. Promoter Methylation of RASSF1A Gene in Egyptian Patients with Ovarian Cancer.
Rezk NA; Mohamed RH; Alnemr AA; Harira M
Appl Biochem Biotechnol; 2018 May; 185(1):153-162. PubMed ID: 29098560
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.
Buderath P; Mairinger F; Mairinger E; Böhm K; Mach P; Schmid KW; Kimmig R; Kasimir-Bauer S; Bankfalvi A; Westerwick D; Hager T
Int J Gynecol Cancer; 2019 Nov; 29(9):1389-1395. PubMed ID: 31492714
[TBL] [Abstract][Full Text] [Related]
15. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
[TBL] [Abstract][Full Text] [Related]
16. Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer.
Mao WM; Li P; Zheng QQ; Wang CC; Ge MH; Hu FJ; Fang XH; Dong ZM; Ling ZQ
Arch Med Res; 2011 Apr; 42(3):182-8. PubMed ID: 21722812
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation.
Parvathareddy SK; Siraj AK; Al-Badawi IA; Tulbah A; Al-Dayel F; Al-Kuraya KS
Sci Rep; 2021 Feb; 11(1):3750. PubMed ID: 33580098
[TBL] [Abstract][Full Text] [Related]
19. Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients.
Rasti M; Tavasoli P; Monabati A; Entezam M
Iran Biomed J; 2009 Oct; 13(4):199-206. PubMed ID: 19946345
[TBL] [Abstract][Full Text] [Related]
20. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma.
Yeo W; Wong N; Wong WL; Lai PB; Zhong S; Johnson PJ
Liver Int; 2005 Apr; 25(2):266-72. PubMed ID: 15780049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
